RestorGenex to Present at Two Upcoming Growth Conferences

BUFFALO GROVE, Ill., Oct. 6, 2015 (GLOBE NEWSWIRE) — RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex’s CEO, will provide a company overview at two upcoming growth conferences featuring biotechnology and pharmaceutical companies.

The first presentation will take place at the 2015 Aegis Growth Conference on October 9, 2015, at 9:00 am PT in The Encore at Wynn Las Vegas, in Las Vegas, Nevada.

The second presentation will take place at the Dawson James Securities Growth Stock Conference on October 15, 2015. The presentation will take place at 11:15 am ET in the Wyndham Grand Hotel in Jupiter, Florida.

The presentation at the Dawson James Conference will be webcast at

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. RestorGenex’s lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. RestorGenex’s novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: